Lung function, respiratory symptoms and venous thromboembolism risk: the Atherosclerosis Risk in Communities Study

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 12, 2016, Pages 2394-2401

  Kubota, Y ^a,b   London, S J ^c   Cushman, M ^d   Chamberlain, A M ^e   Rosamond, W D ^f   Heckbert, S R ^g   Zakai, N ^d   Folsom, A R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f University of North Carolina at Chapel Hill   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chronic obstructive pulmonary disease; lung function; respiratory symptoms; restrictive lung disease; venous thromboembolism

Indexed keywords

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BRONCHUS SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RISK PATIENT; HUMAN; LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHLEGM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; RESTRICTIVE LUNG DISEASE; RISK ASSESSMENT; SPIROMETRY; VENOUS THROMBOEMBOLISM; BLOOD; BREATHING; COMPLICATION; FOLLOW UP; INCIDENCE; LUNG FUNCTION TEST; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; ATHEROSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; LUNG DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SPIROMETRY; VENOUS THROMBOEMBOLISM;

EID: 84998579424     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13525     Document Type: Article

References (35)

1. Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 2003; 112: 203–7.
2. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75.
3. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63–70.
4. Bertoletti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C, Valdés M, Barrón M, Todolí JA, Monreal M; RIETE Investigators. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012; 39: 862–8.
5. Børvik T, Brækkan SK, Enga K, Schirmer H, Brodin EE, Melbye H, Hansen JB. COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J 2016; 47: 473–81.
6. 1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046–51.
7. Fragoso CA, McAvay G, van Ness PH, Casaburi R, Jensen RL, MacIntyre N, Yaggi HK, Gill TM, Concato J. Phenotype of spirometric impairment in an aging population. Am J Respir Crit Care Med 2016; 193: 727–35.
8. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators. Am J Epidemiol 1989; 129: 687–702.
9. Alonso A, Nettleton JA, Ix JH, de Boer IH, Folsom AR, Bidulescu A, Kestenbaum BR, Chambless LE, Jacobs DR Jr. Dietary phosphorus, blood pressure, and incidence of hypertension in the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Hypertension 2010; 55: 776–84.
10. The ARIC Investigators. Atherosclerosis Risk in Communities Study Manual 4: Pulmonary Function. Chapel Hill, NC: Chapel Hill NNH, Lung, and Blood Institute of the National Institutes of Health, Collaborative Studies Coordinating Center, University of North Carolina, 1987.
11. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179–87.
12. Ferris BG. Epidemiology standardization project (AmericanThoracic Society). Am Rev Respir Dis 1978; 118: 1–120.
13. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–65.
14. Rennard S, Thomashow B, Crapo J, Yawn B, McIvor A, Cerreta S, Walsh J, Mannino D. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD 2013; 10: 378–89.
15. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115–22.
16. Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol 2015; 173: M11–21.
17. Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015; 173: R101–13.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–12.
19. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004; 43: 836–45.
20. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 936–42.
21. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19–25.
22. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016; 133: 601–9.
23. Wannamethee SG, Shaper AG, Rumley A, Sattar N, Whincup PH, Thomas MC, Lowe GD. Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care 2010; 33: 1990–6.
24. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758–62.
25. Engström G. The restrictive–obstructive continuum and the failing heart. Thorax 2016; 71: 487–8.
26. Ray CS, Sue DY, Bray G, Hansen JE, Wasserman K. Effects of obesity on respiratory function. Am Rev Respir Dis 1983; 128: 501–6.
27. Schroeder EB, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003; 158: 1171–81.
28. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18–28.
29. Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010; 27: 977–87.
30. Wannamethee SG, Shaper AG, Papacosta O, Lennon L, Welsh P, Whincup PH. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men – the British Regional Heart Study. Thorax 2016; 71: 526–34.
31. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest 2006; 130: 1642–9.
32. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, Loehr LR, McNeill AM, Poole C, Soliman EZ, Heiss G. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014; 129: 971–80.
33. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353–61.
34. Mannino DM, Davis KJ. Lung function decline and outcome in an elderly population. Thorax 2006; 61: 472–7.
35. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis 1991; 144: 1202–18.